Sentiment-Signal
26,0
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
46.7
0 neu, 1 erhöht, -10659766K $ netto
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 22.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Ap |
| 04.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Ap |
| 11.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 28.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | d by the appointment of Dr. Gano as described in Item 5.02 above. A copy of the amendment is attached hereto as Exhibit |
| 23.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 13.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoi |
Stammdaten
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Unternehmen & Branche
| Name | NEUROCRINE BIOSCIENCES INC |
|---|---|
| Ticker | NBIX |
| CIK | 0000914475 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | 64125C109 |
|---|---|
| ISIN | US64125C1099 |
| Typ | Common Stock |
| Marktkapitalisierung | 13,24 Mrd. USD |
| Beta | 0,35 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 2,860,500,000 | 478,600,000 | 4.67 | 4,631,500,000 | 3,253,100,000 |
| 2025-09-30 | 10-Q | 794,900,000 | 209,500,000 | 2.04 | 4,265,700,000 | 3,003,600,000 |
| 2025-06-30 | 10-Q | 687,500,000 | 107,500,000 | 1.06 | 3,889,800,000 | 2,694,300,000 |
| 2025-03-31 | 10-Q | 572,600,000 | 7,900,000 | 0.08 | 3,687,700,000 | 2,535,700,000 |
| 2024-12-31 | 10-K | 2,355,300,000 | 341,300,000 | 3.29 | 3,718,700,000 | 2,589,700,000 |
| 2024-09-30 | 10-Q | 622,100,000 | 129,800,000 | 1.24 | 3,535,000,000 | 2,718,900,000 |
| 2024-06-30 | 10-Q | 590,200,000 | 65,000,000 | 0.63 | 3,305,000,000 | 2,509,200,000 |
| 2024-03-31 | 10-Q | 515,300,000 | 43,400,000 | 0.42 | 3,472,400,000 | 2,386,100,000 |
| 2023-12-31 | 10-K | 1,887,100,000 | 249,700,000 | 2.47 | 3,251,400,000 | 2,232,000,000 |
| 2023-09-30 | 10-Q | 498,800,000 | 83,100,000 | 0.82 | 2,848,200,000 | 2,002,100,000 |
| 2023-06-30 | 10-Q | 452,700,000 | 95,500,000 | 0.95 | 2,613,100,000 | 1,853,000,000 |
| 2023-03-31 | 10-Q | 420,400,000 | -76,600,000 | -0.79 | 2,359,800,000 | 1,684,500,000 |
| 2022-12-31 | 10-K | 1,488,700,000 | 154,500,000 | 1.56 | 2,368,700,000 | 1,707,800,000 |
| 2022-09-30 | 10-Q | 387,900,000 | 68,500,000 | 0.69 | 2,143,400,000 | 1,544,600,000 |
| 2022-06-30 | 10-Q | 378,200,000 | -16,900,000 | -0.18 | 2,005,700,000 | 1,423,400,000 |
| 2022-03-31 | 10-Q | 310,600,000 | 13,900,000 | 0.14 | 2,144,500,000 | 1,391,100,000 |
| 2021-12-31 | 10-K | 1,133,500,000 | 89,600,000 | 0.92 | 2,072,500,000 | 1,374,000,000 |
| 2021-09-30 | 10-Q | 296,000,000 | 22,500,000 | 0.23 | 2,017,300,000 | 1,346,000,000 |
| 2021-06-30 | 10-Q | 288,900,000 | 42,300,000 | 0.43 | 1,956,400,000 | 1,279,200,000 |
| 2021-03-31 | 10-Q | 236,600,000 | 32,100,000 | 0.33 | 1,846,400,000 | 1,205,600,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 12,830,597 | 0 | 12,830,597 | 1,819,763,595 | Neu | +100,0% | |
| VANGUARD GROUP INC | 9,700,301 | 0 | 9,700,301 | 1,375,793,692 | Neu | +100,0% | |
| JPMORGAN CHASE & CO | 5,260,356 | 0 | 5,260,356 | 746,076,419 | Neu | +100,0% | |
| STATE STREET CORP | 4,242,681 | 0 | 4,242,681 | 601,739,446 | Neu | +100,0% | |
| AQR CAPITAL MANAGEMENT LLC | 3,271,706 | 0 | 3,271,706 | 462,651,883 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 2,238,797 | 0 | 2,238,797 | 317,528,579 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 2,059,282 | 0 | 2,059,282 | 291,341,652 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 1,744,560 | 0 | 1,744,560 | 247,430,944 | Neu | +100,0% | |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 1,291,278 | 0 | 1,291,278 | 178,248,014 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 1,221,184 | 0 | 1,221,184 | 173,200,527 | Neu | +100,0% | |
| MORGAN STANLEY | 1,209,378 | 0 | 1,209,378 | 171,526,511 | Neu | +100,0% | |
| NORGES BANK | 1,146,896 | 0 | 1,146,896 | 162,664,260 | Neu | +100,0% | |
| RTW INVESTMENTS, LP | 1,062,072 | 0 | 1,062,072 | 150,633,672 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 984,811 | 0 | 984,811 | 139,675,744 | Neu | +100,0% | |
| UBS Group AG | 983,528 | 0 | 983,528 | 139,493,777 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 850,632 | 0 | 850,632 | 120,645,137 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 776,934 | 0 | 776,934 | 110,304,874 | Neu | +100,0% | |
| IEQ CAPITAL, LLC | 745,113 | 0 | 745,113 | 105,679,358 | Neu | +100,0% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 722,476 | 0 | 722,476 | 102,468,771 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 716,475 | 0 | 716,475 | 101,611,949 | Neu | +100,0% | |
| Fiera Capital Corp | 637,408 | 0 | 637,408 | 90,403,576 | Neu | +100,0% | |
| RAYMOND JAMES FINANCIAL INC | 631,422 | 0 | 631,422 | 89,220,928 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 585,677 | 0 | 585,677 | 83,066,515 | Neu | +100,0% | |
| Swedbank AB | 584,129 | 0 | 584,129 | 82,847,016 | Neu | +100,0% | |
| ALLIANCEBERNSTEIN L.P. | 555,494 | 0 | 555,494 | 78,785,714 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 532,759 | 0 | 532,759 | 75,561,209 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 528,104 | 0 | 528,104 | 74,901,036 | Neu | +100,0% | |
| PRIMECAP MANAGEMENT CO/CA/ | 507,740 | 0 | 507,740 | 72,012,765 | Neu | +100,0% | |
| JANUS HENDERSON GROUP PLC | 459,176 | 0 | 459,176 | 65,127,039 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 442,866 | 0 | 442,866 | 62,811,685 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 367,944 | 0 | 367,944 | 52,185,497 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 367,035 | 0 | 367,035 | 52,056,503 | Neu | +100,0% | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 360,711 | 0 | 360,711 | 51,159,641 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 348,843 | 0 | 348,843 | 49,476,400 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 347,013 | 0 | 347,013 | 49,216,854 | Neu | +100,0% | |
| Invesco Ltd. | 343,421 | 0 | 343,421 | 48,707,399 | Neu | +100,0% | |
| Allspring Global Investments Holdings, LLC | 339,432 | 0 | 339,432 | 47,724,140 | Neu | +100,0% | |
| PERCEPTIVE ADVISORS LLC | 331,050 | 0 | 331,050 | 46,952,821 | Neu | +100,0% | |
| Legal & General Group Plc | 330,606 | 0 | 330,606 | 46,889,844 | Neu | +100,0% | |
| ROYAL BANK OF CANADA | 311,012 | 0 | 311,012 | 44,110,000 | Neu | +100,0% | |
| Clearbridge Investments, LLC | 310,077 | 0 | 310,077 | 43,978,221 | Neu | +100,0% | |
| Hudson Bay Capital Management LP | 305,000 | 0 | 305,000 | 43,258,150 | Neu | +100,0% | |
| RHUMBLINE ADVISERS | 297,444 | 0 | 297,444 | 42,186,394 | Neu | +100,0% | |
| Candriam S.C.A. | 293,096 | 0 | 293,096 | 41,571,575 | Neu | +100,0% | |
| Rockefeller Capital Management L.P. | 507,170 | 0 | 507,170 | 39,863,017 | Neu | +100,0% | |
| Swiss National Bank | 271,800 | 0 | 271,800 | 38,549,394 | Neu | +100,0% | |
| RENAISSANCE GROUP LLC | 252,293 | 0 | 252,293 | 35,782,711 | Neu | +100,0% | |
| BARCLAYS PLC | 252,241 | 0 | 252,241 | 35,775,341 | Neu | +100,0% | |
| Connor, Clark & Lunn Investment Management Ltd. | 246,289 | 0 | 246,289 | 34,931,169 | Neu | +100,0% | |
| WELLS FARGO & COMPANY/MN | 242,111 | 0 | 242,111 | 34,338,697 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-16 | Gano Kyle | Director, Officer, Chief Executive Officer | Open Market Sale | -1,812 | 132.71 | -240,478.31 | -8,9% | |
| 2026-01-16 | Gano Kyle | Director, Officer, Chief Executive Officer | Open Market Sale | -34,588 | 132.70 | -4,589,979.79 | -170,7% | |
| 2025-12-16 | Norwalk Leslie V | Director | Open Market Sale | -1,190 | 155.09 | -184,558.41 | -6,9% | |
| 2025-12-15 | Norwalk Leslie V | Director | Open Market Sale | -5,000 | 152.23 | -761,143.50 | -28,3% | |
| 2025-12-08 | Lippoldt Darin | Officer, Chief Legal Officer | Open Market Sale | -4,376 | 159.65 | -698,615.27 | -26,0% | |
| 2025-12-03 | LYONS GARY A | Director | Open Market Sale | -15,000 | 152.61 | -2,289,082.50 | -85,1% | |
| 2025-11-28 | BENEVICH ERIC | Officer, Chief Commercial Officer | Open Market Sale | -5,970 | 151.74 | -905,880.64 | -33,7% | |
| 2025-11-25 | MORROW GEORGE J | Director | Open Market Sale | -15,000 | 143.37 | -2,150,512.50 | -80,0% | |
| 2025-11-05 | RASTETTER WILLIAM H | Director | Open Market Sale | -18,000 | 151.82 | -2,732,689.80 | -101,6% | |
| 2025-11-04 | Gano Kyle | Director, Officer, Chief Executive Officer | Open Market Sale | -300 | 141.97 | -42,591.00 | -1,6% | |
| 2025-08-07 | GORMAN KEVIN CHARLES | Director | Open Market Sale | -106,322 | 126.41 | -13,440,280.97 | -499,9% | |
| 2025-07-10 | Delaet Ingrid | Officer, Chief Regulatory Officer | Open Market Sale | -457 | 135.00 | -61,695.00 | -2,3% | |
| 2025-07-09 | Onyia Jude | Officer, Chief Scientific Officer | Open Market Sale | -59,819 | 130.46 | -7,803,687.65 | -290,3% | |
| 2025-07-02 | Onyia Jude | Officer, Chief Scientific Officer | Open Market Sale | -20,362 | 130.13 | -2,649,737.60 | -98,6% | |
| 2025-05-27 | GORMAN KEVIN CHARLES | Director | Open Market Sale | -9,613 | 120.38 | -1,157,211.02 | -43,0% | |
| 2025-05-05 | RASTETTER WILLIAM H | Director | Open Market Sale | -30,000 | 110.20 | -3,305,952.00 | -123,0% |
Fail-to-Deliver (6 Monate)
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-03-31 | 1.796 | 128,72 | 231.181 |
| 2026-03-23 | 2 | 127,68 | 255 |
| 2026-02-23 | 19.850 | 128,63 | 2.553.306 |
Top-Fondshalter
Stand: 31.03.2026
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| OPPENHEIMER & CO INC | 42,079 | 5,543,487 | 100.00 |